# Evaluation of RC28-E Injection in Diabetic Macular Edema

> **NCT04782115** · PHASE2 · COMPLETED · sponsor: **RemeGen Co., Ltd.** · enrollment: 156 (actual)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **BIOLOGICAL:** intravitreal injection of RC28-E
- **BIOLOGICAL:** Conbercept

## Key facts

- **NCT ID:** NCT04782115
- **Lead sponsor:** RemeGen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-17
- **Primary completion:** 2023-07-31
- **Final completion:** 2023-07-31
- **Target enrollment:** 156 (ACTUAL)
- **Last updated:** 2023-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04782115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04782115, "Evaluation of RC28-E Injection in Diabetic Macular Edema". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT04782115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*